Veteran private markets investor and operating executive focused on growth-stage technology and healthcare companies. Brett Pohl brings experience in scaling commercial teams, board-level governance and capital raising, with a track record advising startups through Series A–C financings and strategic exits. Previously led business development and corporate strategy roles at software and services firms and has worked closely with venture capital and growth equity funds. Active in board and investor relations, with emphasis on go-to-market execution, revenue operations and M&A preparation. Provides LP-facing reporting and portfolio construction input for institutional and high-net-worth accounts.
Veteran private markets investor and operating executive focused on growth-stage technology and healthcare companies. Brett Pohl brings experience in scaling commercial teams, board-level governance and capital raising, with a track record advising startups through Series A–C financings and strategic exits. Previously led business development and corporate strategy roles at software and services firms and has worked closely with venture capital and growth equity funds. Active in board and investor relations, with emphasis on go-to-market execution, revenue operations and M&A preparation. Provides LP-facing reporting and portfolio construction input for institutional and high-net-worth accounts.
Focuses on growth-stage technology and healthcare investments, prioritizing companies with scalable go-to-market models and clear paths to profitable unit economics. Favors active, board-level engagement to accelerate revenue operations, customer expansion and M&A readiness. Allocates capital with stage-focused discipline—concentrated follow-on reserves for winners—combining sector expertise, commercial scaling playbooks and rigorous diligence on sales motion and GTM metrics. Time horizon is multi-year growth-to-exit, balancing growth orientation with pragmatic capital efficiency and LP reporting transparency.
Focuses on growth-stage technology and healthcare investments, prioritizing companies with scalable go-to-market models and clear paths to profitable unit economics. Favors active, board-level engagement to accelerate revenue operations, customer expansion and M&A readiness. Allocates capital with stage-focused discipline—concentrated follow-on reserves for winners—combining sector expertise, commercial scaling playbooks and rigorous diligence on sales motion and GTM metrics. Time horizon is multi-year growth-to-exit, balancing growth orientation with pragmatic capital efficiency and LP reporting transparency.
| Trades 662 | Longs Won 453/662 68% | Profit Factor 9.29 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $395,120.41 |
| Average Win $143,019.15 | Best Trade (Jul 10) $4.84M | Sharpe Ratio -9.67 |
| Average Loss -$33,381.21 | Worst Trade (Jul 10) -$1.41M | Z-Score 1.57 (88.42%) |
| Commissions $0 | Avg. Trade Length 1y 3w | Expectancy $87,327.79 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 5,319 | 4,787 | 4,255 | 3,723 | 3,191 | 2,660 | 2,128 | 1,596 | 1,064 | 532 |